Spironolactone in congestive heart failure

Current Hypertension Reports

Volumn 2, Issue 5, 2000, Pages 451-456

  Soberman, Judith E ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

ANIMAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ALDOSTERONE; SPIRONOLACTONE;

EID: 0034295520     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-000-0027-x     Document Type: Article

References (41)

1. Gheorghiade M, Cody RJ, Francis GS, et al.: Current medical therapy for advanced heart failure. Am Heart J 1998, 132: S231-S248.
2. O'Connor CM, Gattis WA, Swedberg K: Current and novel pharmacologic approaches in advanced heart failure. Am Heart J 1998, 135: S249-S263.
3. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341: 709-717. The RALES trial demonstrates a 30% reduction in total mortality among patients receiving low-dose spironolactone. This lower risk was attributed to both a reduction in progressive heart failure and sudden cardiac death. Hospitalization for worsening heart failure was also significantly decreased in the spironolactone group.
4. MacFadyen RJ, Barr CS, Struthers AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997, 35: 30-34. This article presents the first human data demonstrating that spironolactone, added to ACE inhibitor treatment, improves heart rate variability and reduces myocardial collagen turnover.
5. Zannad F: Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. Am J Cardiol 1993, 71: 34A-39A.
6. Tait J F, Bougas J, Little B, et al.: Splanchnic extraction and clearance of aldosterone in subjects with minimal and marked cardiac dysfunction. J Clin Endocrinol 1965, 25: 219-228.
7. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82: 1730-1736.
8. Eichhorn EJ, Tandon PK, Di Bianco R, et al.: Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. J Am Coll Cardiol 1993, 21: 634-640.
9. Tsuji H, Venditti FJ Jr, Evans JC, et al.: The association of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol 1994, 74: 232-235.
10. Gottlieb SS, Baruch L, Kukin ML, et al.: Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol 1990, 16: 827-831.
11. Struthers AD: Two new culprits in cardiovascular disease: QT dispersion and aldosterone. J Hum Hypertens 1995, 9: 659-661.
12. Barr CS, Lang CC, Hanson J, et al.: Effects of adding Spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995, 76: 1259-1265.
13. Brilla CG, Weber KT: Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992, 26: 671-677.
14. Sun Y, Ramires FJA, Weber KT: Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997, 35: 138-147. Atrial and perivascular fibrosis of the great vessels was seen in response to angiotensin II or aldosterone independent of arterial hypertension or wall stress in an animal model.
15. Robert V, Van Thiem N, Cheav SL, et al.: Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994, 24: 30-36.
16. Barr CS, Naas A, Freeman N, et al.: QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994, 343: 327-329.
17. Wang W, McClain JM, Zucker IH: Aldosterone reduces baroreceptor discharge in the dog. Hypertension 1992, 19: 270-277.
18. Struthers AD: Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure? Br J Clin Pharmacol 1999, 47: 479-482.
19. Frishman WH: Recent advances in cardiovascular pharmacology. Curr Probl Cardiol 2000, 25: 227-295.
20. Pfeffer MA, Braunwald E, Moy LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992, 327: 669-677.
21. Weber KT, Villarreal D: Role of aldosterone in congestive heart failure. Postgrad Med 1993, 93(5):203-207.
22. Struthers AD: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995, 16(suppl N):103-106.
23. Bashir Y, Sneddon J F, Staunton HA, et al.: Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1993, 72: 1156-1162.
24. Kelly RA, Smith TW: Drugs used in the treatment of heart failure. In Heart Disease: A Textbook of Cardiovascular Medicine 5th edn. Edited by Braunwald E. Philadelphia: W. B. Saunders; 1997: 471-491.
25. Weber MA, Purdy RE, Drayer JI: Interactions of mineralocorticoids and pressor agents in vascular smooth muscle. Hypertension 1983, 5(2 pt 2): I41-I46.
26. Farquharson CAJ, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101: 594-597. The use of spironolactone improves endothelial dysfunction in patients with CHF on ACE inhibitors.
27. Lombès M, Oblin M-E, Gasc J-M, et al.: Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992, 71: 503-510.
28. Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242: 583-585.
29. Sun Y, Ratajska A, Zhou G, Weber KT: Angiotensin converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med 1993, 122: 395-403.
30. Brilla CG, Pick R, Tan LB, et al.: Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990, 67: 1355-1364.
31. Campbell SE, Farb A, Weber KT: Pathologic remodeling of the myocardium in a weightlifter taking anabolic steroids. Blood Press 1993, 2: 2 1 3-2 1 6.
32. Brilla CG, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25: 563-575.
33. Young M, Head G, Funder J: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995, 269: E657-E662.
34. Klappacher G, Franzen P, Haab D, et al.: Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995, 75: 9 1 3-9 1 8.
35. Host NB, Jensen LT, Bendixen PM, et al.: The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol 1995, 76: 869-873.
36. Moser DK, Stevenson WG, Woo MA, Stevenson LW: Timing of sudden death in patients with heart failure. J Am Coll Cardiol 1994, 24: 963-967.
37. Physicians' Desk Reference. 53rd edn. Montvale, NJ: Medical Economics; 1999.
38. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316: 1429-1435.
39. Effectiveness of spironolactone added to an angiotensinconverting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996, 78: 902-907.
40. Pitt D: ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J 1995, 16(suppl N):107-110.
41. Cody RJ: The clinical potential of renin inhibitors and angiotensin antagonists. Drugs 1994, 47: 586-598.